Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
Bohdana Doskaliuk,Naveen Ravichandran,Parikshit Sen,Jessica Day,Mrudula Joshi,Arvind Nune,Elena Nikiphorou,Sreoshy Saha,Ai Lyn Tan,Samuel Katsuyuki Shinjo,Nelly Ziade,Tsvetelina Velikova,Marcin Milchert,Kshitij Jagtap,Ioannis Parodis,Abraham Edgar Gracia-Ramos,Lorenzo Cavagna,Masataka Kuwana,Johannes Knitza,Yi Ming Chen,Ashima Makol,Vishwesh Agarwal,Aarat Patel,John D Pauling,Chris Wincup,Bhupen Barman,Erick Adrian Zamora Tehozol,Jorge Rojas Serrano,Ignacio García-De La Torre,Iris J Colunga-Pedraza,Javier Merayo-Chalico,Okwara Celestine Chibuzo,Wanruchada Katchamart,Phonpen Akarawatcharangura Goo,Russka Shumnalieva,Leonardo Santos Hoff,Lina El Kibbi,Hussein Halabi,Binit Vaidya,Syahrul Sazliyana Shaharir,A T M Tanveer Hasan,Dzifa Dey,Carlos Enrique Toro Gutiérrez,Carlo V Caballero-Uribe,James B Lilleker,Babur Salim,Tamer Gheita,Tulika Chatterjee,Oliver Distler,Miguel A Saavedra,COVAD study group,Hector Chinoy,Vikas Agarwal,Rohit Aggarwal,Latika Gupta,Sinan Kardes,Laura Andreoli,Daniele Lini,Karen Schreiber,Melinda Nagy Vince,Yogesh Preet Singh,Rajiv Ranjan,Avinash Jain,Sapan C Pandya,Rakesh Kumar Pilania,Aman Sharma,Manesh Manoj M,Vikas Gupta,Chengappa G Kavadichanda,Pradeepta Sekhar Patro,Sajal Ajmani,Sanat Phatak,Rudra Prosad Goswami,Abhra Chandra Chowdhury,Ashish Jacob Mathew,Padnamabha Shenoy,Ajay Asranna,Keerthi Talari Bommakanti,Anuj Shukla,Arunkumar R Pande,Kunal Chandwar,Akanksha Ghodke,Hiya Boro,Zoha Zahid Fazal,Döndü Üsküdar Cansu,Reşit Yıldırım,Armen Yuri Gasparyan Nicoletta Gianluca Del PapaSambataro,Atzeni Fabiola,Marcello Govoni Simone Parisi,Elena Bartoloni Bocci,Gian Domenico Sebastiani,Enrico Fusaro,Marco Sebastiani Luca Quartuccio,Franco Franceschini,Pier Paolo Sainaghi Giovanni Orsolini,Rossella Maria Giovanna Danielli Vincenzo De AngelisVenerito,Silvia Grignaschi,Alessandro Giollo,Alessia Alluno,Florenzo Ioannone,Marco Fornaro,Lisa S Traboco,Suryo Anggoro Kusumo Wibowo,Jesús Loarce-Martos,Sergio Prieto-González,Raquel Aranega Gonzalez,Akira Yoshida,Ran Nakashima,Shinji Sato,Naoki Kimura,Yuko Kaneko,Takahisa Gono,Stylianos Tomaras,Fabian Nikolai Proft,Marie-Therese Holzer,Margarita Aleksandrovna Gromova,Or Aharonov,Zoltán Griger,Ihsane Hmamouchi,Imane El Bouchti,Zineb Baba,Margherita Giannini,François Maurier,Julien Campagne,Alain Meyer,Daman Langguth,Vidya Limaye,Merrilee Needham,Nilesh Srivastav,Marie Hudson Océane Landon-Cardinal,Wilmer Gerardo Rojas Zuleta,Álvaro Arbeláez Javier Cajas,José António Pereira Silva,João Eurico Fonseca,Olena Zimba Doskaliuk Bohdana,Uyi Ima-Edomwonyi,Ibukunoluwa Dedeke,Emorinken Airenakho,Nwankwo Henry Madu,Abubakar Yerima,Hakeem Olaosebikan,Becky A,Oruma Devi Koussougbo,Elisa Palalane,Ho So,Manuel Francisco Ugarte-Gil,Lyn Chinchay,José Proaño Bernaola,Victorio Pimentel,Hanan Mohammed Fathi,Reem Hamdy A Mohammed,Ghita Harifi,Yurilís Fuentes-Silva Karoll Cabriza,Jonathan Losanto,Nelly Colaman,Antonio Cachafeiro-Vilar,Generoso Guerra Bautista,Enrique Julio Giraldo Ho,Lilith Stange Nunez,Cristian Vergara M,Jossiell Then Báez,Hugo Alonzo,Carlos Benito Santiago Pastelin,Rodrigo García Salinas,Alejandro Quiñónez Obiols,Nilmo Chávez,Andrea Bran Ordóñez,Gil Alberto Reyes Llerena,Radames Sierra-Zorita,Dina Arrieta,Eduardo Romero Hidalgo,Ricardo Saenz,Idania Escalante M,Wendy Calapaqui,Ivonne Quezada,Gabriela Arredondo
DOI: https://doi.org/10.1007/s00296-023-05345-y
Abstract:Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.